File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1158/1078-0432.CCR-05-0648
- Scopus: eid_2-s2.0-23844440912
- PMID: 16115906
- WOS: WOS:000231320000009
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: A comparison study of different PCR assays in measuring circulating plasma Epstein-Barr virus DNA levels in patients with nasopharyngeal carcinoma
Title | A comparison study of different PCR assays in measuring circulating plasma Epstein-Barr virus DNA levels in patients with nasopharyngeal carcinoma |
---|---|
Authors | |
Issue Date | 2005 |
Citation | Clinical Cancer Research, 2005, v. 11, n. 16, p. 5700-5707 How to Cite? |
Abstract | Purpose: To compare the performance of three PCR assays in measuring circulating Epstein-Barr virus (EBV). DNA levels in nasopharyngeal carcinoma patients and to confirm its prognostic significance. Experimental Design: Plasma from 58 newly diagnosed nasopharyngeal carcinoma patients were collected before, during, and every 3 to 6 months after radiotherapy. EBV DNA levels were determined by real-time quantitative PCR using primer/probe sets for polymerase-1 (Pol-1), latent membrane protein 2 (Lmp2), and BamHI-W. Pretreatment levels from the three assays were correlated with each other and serial measurements from the Pol-1 assay were correlated with clinical variables. Results: Pol-1 was more accurate than BamHI-W in predicting EBV DNA concentrations in cell lines. Ofthe three assays, BamHI-W yielded the highest concentrations followed by Pol-1 in plasmas (n = 23). The correlation coefficient was 0.99 (P < 0.0001) for Pol-1 and Lmp2, 0.66 (P < 0.0001) for Pol-1 and BamHI-W, and 0.55 (P < 0.0001) for BamHI-W and Lmp2. Elevated pretreatment DNA levels as detected by Pol-1 were correlated with advanced nodal stage (P = 0.04) and overall stage (P = 0.028). There was no correlation between pretreatment EBV DNA levels and freedom-from-relapse or overall survival; however, there was a significant correlation between posttreatment levels and these variables. The 2-year freedom-from-relapse and overall survival rates were 92% and 94% for patients with undetectable, and 37% and 55% for those with detectable, posttreatment levels (P < 0.0001 and P < 0.002). Conclusions: The three PCR assays yielded similar results in detecting EBV DNA in plasmas. The Pol-7-detected posttreatment EBV DNA level was the strongest predictor for treatment outcomes. © 2005 American Association for Cancer Research. |
Persistent Identifier | http://hdl.handle.net/10722/213894 |
ISSN | 2023 Impact Factor: 10.0 2023 SCImago Journal Rankings: 4.623 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Le, Quynh Thu | - |
dc.contributor.author | Jones, Carol D. | - |
dc.contributor.author | Yau, Tsz Kok | - |
dc.contributor.author | Shirazi, Haider A. | - |
dc.contributor.author | Wong, Priscilla H. | - |
dc.contributor.author | Thomas, Ella N. | - |
dc.contributor.author | Patterson, Bruce K. | - |
dc.contributor.author | Lee, Anne W M | - |
dc.contributor.author | Zehnder, James L. | - |
dc.date.accessioned | 2015-08-19T13:41:07Z | - |
dc.date.available | 2015-08-19T13:41:07Z | - |
dc.date.issued | 2005 | - |
dc.identifier.citation | Clinical Cancer Research, 2005, v. 11, n. 16, p. 5700-5707 | - |
dc.identifier.issn | 1078-0432 | - |
dc.identifier.uri | http://hdl.handle.net/10722/213894 | - |
dc.description.abstract | Purpose: To compare the performance of three PCR assays in measuring circulating Epstein-Barr virus (EBV). DNA levels in nasopharyngeal carcinoma patients and to confirm its prognostic significance. Experimental Design: Plasma from 58 newly diagnosed nasopharyngeal carcinoma patients were collected before, during, and every 3 to 6 months after radiotherapy. EBV DNA levels were determined by real-time quantitative PCR using primer/probe sets for polymerase-1 (Pol-1), latent membrane protein 2 (Lmp2), and BamHI-W. Pretreatment levels from the three assays were correlated with each other and serial measurements from the Pol-1 assay were correlated with clinical variables. Results: Pol-1 was more accurate than BamHI-W in predicting EBV DNA concentrations in cell lines. Ofthe three assays, BamHI-W yielded the highest concentrations followed by Pol-1 in plasmas (n = 23). The correlation coefficient was 0.99 (P < 0.0001) for Pol-1 and Lmp2, 0.66 (P < 0.0001) for Pol-1 and BamHI-W, and 0.55 (P < 0.0001) for BamHI-W and Lmp2. Elevated pretreatment DNA levels as detected by Pol-1 were correlated with advanced nodal stage (P = 0.04) and overall stage (P = 0.028). There was no correlation between pretreatment EBV DNA levels and freedom-from-relapse or overall survival; however, there was a significant correlation between posttreatment levels and these variables. The 2-year freedom-from-relapse and overall survival rates were 92% and 94% for patients with undetectable, and 37% and 55% for those with detectable, posttreatment levels (P < 0.0001 and P < 0.002). Conclusions: The three PCR assays yielded similar results in detecting EBV DNA in plasmas. The Pol-7-detected posttreatment EBV DNA level was the strongest predictor for treatment outcomes. © 2005 American Association for Cancer Research. | - |
dc.language | eng | - |
dc.relation.ispartof | Clinical Cancer Research | - |
dc.title | A comparison study of different PCR assays in measuring circulating plasma Epstein-Barr virus DNA levels in patients with nasopharyngeal carcinoma | - |
dc.type | Article | - |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1158/1078-0432.CCR-05-0648 | - |
dc.identifier.pmid | 16115906 | - |
dc.identifier.scopus | eid_2-s2.0-23844440912 | - |
dc.identifier.hkuros | 266071 | - |
dc.identifier.volume | 11 | - |
dc.identifier.issue | 16 | - |
dc.identifier.spage | 5700 | - |
dc.identifier.epage | 5707 | - |
dc.identifier.isi | WOS:000231320000009 | - |
dc.identifier.issnl | 1078-0432 | - |